Key Takeaway
Explore the latest PT-141 research studies covering clinical trials, efficacy data, and emerging findings on this melanocortin receptor agonist peptide.
| Peptide Q&A
PT-141 (bremelanotide) research studies span over two decades of clinical investigation, primarily focused on sexual dysfunction in both men and women. The peptide works through melanocortin receptors in the central nervous system rather than the vascular system, distinguishing it from PDE5 inhibitors. Multiple Phase III clinical trials led to FDA approval of the commercial version (Vyleesi) in 2019 for hypoactive sexual desire disorder in premenopausal women.
Early Research and Discovery
PT-141 originated from research on Melanotan II, a synthetic peptide initially developed for sunless tanning. During early trials, researchers observed unexpected pro-sexual effects in participants. This led to the isolation of the specific pharmacophore responsible for sexual arousal responses, which became PT-141.
The University of Arizona played a central role in early PT-141 research during the late 1990s. Preclinical studies in animal models demonstrated that the peptide activated melanocortin-4 receptors (MC4R) in the brain, triggering arousal pathways independent of blood flow changes.
Clinical Trials in Women
The RECONNECT studies were two important Phase III trials involving over 1,200 premenopausal women with hypoactive sexual desire disorder (HSDD). Participants self-administered 1.75 mg subcutaneous injections before anticipated sexual activity. Results showed statistically significant improvements in desire and reductions in distress compared to placebo.
Key findings from the female-focused trials include:
- Meaningful increases in satisfying sexual events per month
- Improved scores on the Female Sexual Function Index
- Reduced distress as measured by the Female Sexual Distress Scale
- Effects observed within the first month of use
Research in Male Sexual Dysfunction
Earlier Phase II studies examined PT-141 in men with erectile dysfunction, including those who did not respond to PDE5 inhibitors like sildenafil. Intranasal formulations showed promising results in producing erections, though the FDA ultimately did not approve PT-141 for male use due to blood pressure concerns with the nasal delivery method.
From the FormBlends catalog
PT-141 (Bremelanotide)
for women with low sexual desire. · From $189/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View PT-141 (Bremelanotide) →Subcutaneous administration in male studies showed fewer cardiovascular side effects, and ongoing research continues to explore this route for potential male applications. PT-141 side effects men
Emerging Research Areas
Beyond sexual health, researchers are investigating PT-141 in several newer areas:
- Hemorrhagic shock: Animal studies suggest melanocortin agonists may help restore blood pressure and organ perfusion during severe blood loss.
- Inflammation: MC4R activation has shown anti-inflammatory properties in preclinical models.
- Metabolic effects: Some research explores connections between melanocortin pathways and appetite regulation.
Safety Data From Studies
Across clinical trials, the most commonly reported side effects included nausea (affecting roughly 40% of participants), flushing, headache, and injection site reactions. Nausea was the primary reason for discontinuation in the RECONNECT trials. The FDA labeling limits use to no more than one dose per 24 hours and no more than eight doses per month.
Long-term safety studies spanning 12 months showed no new safety signals beyond those identified in shorter trials. Researchers noted that nausea tended to decrease with repeated use in many participants. PT-141 side effects
Current Research space
Ongoing studies are exploring alternative delivery methods, combination therapies, and expanded indications. Researchers continue to investigate whether lower doses or modified administration schedules might reduce side effects while maintaining efficacy. The peptide research community also examines structural analogs of PT-141 that may offer improved selectivity for specific melanocortin receptor subtypes. PT-141 dosage guide
Frequently Asked Questions
How many clinical trials have been conducted on PT-141?
PT-141 has been studied in numerous clinical trials over more than 20 years, including multiple Phase II and two important Phase III trials (the RECONNECT studies) that enrolled over 1,200 women. Additional Phase II studies were conducted in men with erectile dysfunction.
What did research show about PT-141 for men?
Phase II trials in men with erectile dysfunction showed that PT-141 could produce erections even in patients who did not respond to Viagra. But the intranasal delivery method raised blood pressure concerns, and the peptide was not approved for male use. Subcutaneous delivery showed a better safety profile.
Is PT-141 still being researched?
Yes. While PT-141 has an approved commercial form (Vyleesi) for HSDD in premenopausal women, researchers continue to study alternative delivery methods, expanded patient populations, and novel applications including hemorrhagic shock and inflammation.
How does PT-141 differ from Viagra in research findings?
Research shows PT-141 works through a completely different mechanism. While Viagra increases blood flow by inhibiting PDE5, PT-141 activates melanocortin receptors in the brain to stimulate arousal centrally. This means PT-141 addresses desire rather than just the physical mechanics of sexual response.
What were the main side effects found in PT-141 studies?
Nausea was the most common side effect, reported by approximately 40% of trial participants. Other frequently reported effects included flushing, headache, and injection site reactions. Most side effects were transient and mild to moderate in severity.
Ready when you are
PT-141 (Bremelanotide)
for women with low sexual desire. · From $189/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View PT-141 (Bremelanotide) →